Meta‐analysis of the immunogenicity of standard and booster SARS‐CoV‐2 vaccination in patients with chronic liver disease and post‐liver transplantation DOI Creative Commons

Wen‐Xin Wang,

Jitao Wang, Jia Rui

et al.

Portal hypertension & cirrhosis, Journal Year: 2023, Volume and Issue: 2(2), P. 61 - 77

Published: June 1, 2023

Abstract Aims Patients with liver disease may exhibit higher infection rates and mortality from coronavirus 2019 (COVID‐19) than healthy individuals, vaccination against severe acute respiratory syndrome 2 (SARS‐CoV‐2) is an effective prevention strategy. This meta‐analysis aimed to assess the effectiveness safety of SARS‐CoV‐2 vaccines in patients chronic (CLD) post‐liver transplantation (LT). Methods The PubMed, Embase, Cochrane databases were searched. A random‐effects model was used determine seropositivity antibodies, odds ratio (OR) compared controls (HC), risk (RR) between booster standard regimen, rate adverse reactions (ADR). Results In regimen analysis, 17 controlled articles included for six ADR analysis. pooled antibodies CLD post‐LT 93.3% (95% confidence interval [CI]: 89.0%–97.6%) 69.1% CI: 63.0%–75.3%), respectively. Both lower those HC ( p < 0.001). differences remained significant after sorting by detection interval, vaccine type, antibody or type. LT recipients showed much (69.1% vs. 93.3%) (OR: 0.055). total 24.0% 16.2%–31.8%). 11 prospective studies enrolled, dose increased 27% (RR: 1.27, 95% 1.15–1.41, Conclusion can gain protection COVID‐19 vaccines, demonstrating a potentially weaker immunogenic response HC. Booster compensate this deficiency. Therefore, should be prioritized receiving vaccine.

Language: Английский

Vaccination in liver diseases and liver transplantation: Recommendations, implications and opportunities in the post-COVID era DOI Creative Commons
María Pilar Ballester, Rajiv Jalan, Gautam Mehta

et al.

JHEP Reports, Journal Year: 2023, Volume and Issue: 5(8), P. 100776 - 100776

Published: April 26, 2023

The interest in vaccination efficacy and toxicity has surged following the COVID-19 pandemic. Immune responses to several vaccines have been shown be suboptimal patients with chronic liver disease (CLD) transplant (LT) recipients, as a consequence of cirrhosis-associated immune dysfunction or post-LT immunosuppression, respectively. Accordingly, vaccine-preventable infections may more common severe those than general population. pandemic greatly accelerated research development into technology platforms, which will spillover benefits for disease. aims this review are: (i) discuss impact on CLD LT (ii) appraise current evidence supporting strategies, (iii) provide some insight recent developments relevant

Language: Английский

Citations

15
SARS-CoV-2 Infection and Liver Disease: A Review of Pathogenesis and Outcomes DOI Creative Commons
Luke Baldelli, Thomas Marjot, Eleanor Barnes

et al.

Gut and Liver, Journal Year: 2022, Volume and Issue: 17(1), P. 12 - 23

Published: Dec. 2, 2022

The impact of the coronavirus disease 2019 (COVID-19) pandemic has been immense, and it continues to have lasting repercussions.While severe acute respiratory syndrome 2 (SARS-CoV-2) virus primarily infects system, other organ systems are affected, including liver.Scientific knowledge on role SARS-CoV-2 infection liver injury evolved rapidly, with recent data suggesting specific hepatotropism SARS-CoV-2.Moreover, additional concerns raised in regard long-term damage, related emerging cases post-COVID-19 cholangiopathy chronic cholestasis.Great effort also focused studying how subpopulations medical conditions might be disproportionately impacted by COVID-19.One such population includes individuals (CLD) cirrhosis, an expanding body research indicating these patients being particularly susceptible adverse outcomes.In this review, we provide updated summary current pathogenesis mechanism setting infection, association between health outcomes CLD, unique consequences COVID-19 routine care CLD.(Gut Liver

Language: Английский

Citations

15
Omicron infections profile and vaccination status among 1881 liver transplant recipients: a multi-centre retrospective cohort DOI Creative Commons

Ensi Ma,

Jingwen Ai, Yi Zhang

et al.

Emerging Microbes & Infections, Journal Year: 2022, Volume and Issue: 11(1), P. 2636 - 2644

Published: Oct. 13, 2022

A wave of Omicron infections rapidly emerged in China 2022, but large-scale data concerning the safety profile vaccines and Coronavirus disease 2019 (COVID-19) infection features liver transplant (LT) recipients have not been collected. Therefore, aim this study was to assess protectiveness inactivated LT patients against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant infections. multi-centre retrospective conducted a cohort with history transplantation. total 1881 participants (487 vaccinated 1394 unvaccinated patients) were enrolled from seven centres China. Fourteen infected by Omicron, 50% had over 14 days viral shedding duration. The protection rate COVID-19 vaccinations 2.59%. three breakthrough occurred more than 6 months after fully vaccinated. 96 (19.7%) adverse events, including fatigue, myalgia, dysfunction, swelling, scleroma. There Grade 3 events preoperative vaccination group those postoperative group. Inactivated whole-virion SARS-CoV-2 are safe post-liver efficacy decreases vaccination, it is recommended that get boosted as early possible even when they Although clinical manifestations mild patients, might higher risk dysfunction during

Language: Английский

Citations

14
Immunogenicity of a third dose of inactivated COVID-19 vaccine in people living with HIV-1, HBV, and tuberculosis during the Omicron variant epidemic: A cross-sectional study DOI Open Access
Yan Yan,

Chantsalmaa Davgadorj,

Chunyan Lyu

et al.

Journal of Infection, Journal Year: 2022, Volume and Issue: 85(4), P. e109 - e111

Published: July 5, 2022

Language: Английский

Citations

12
Antibody Response and Safety of ChAdOx1-nCOV (Covishield) in Patients with Cirrhosis: A Cross-Sectional, Observational Study DOI Open Access
Amandeep Singh, Arka De, Mini P. Singh

et al.

Digestive Diseases and Sciences, Journal Year: 2022, Volume and Issue: 68(2), P. 676 - 684

Published: Sept. 25, 2022

Language: Английский

Citations

11
Safety and Immunogenicity of Anti-SARS-CoV-2 Booster Dose in Patients with Chronic Liver Disease DOI Open Access
Valentina Cossiga, Mario Capasso, Maria Guarino

et al.

Journal of Clinical Medicine, Journal Year: 2023, Volume and Issue: 12(6), P. 2281 - 2281

Published: March 15, 2023

The low response to vaccines is a well-known problem in cirrhosis. We evaluated the safety and immunogenicity of booster doses patients with chronic liver disease (CLD), comparing humoral cirrhotic vs. non-cirrhotic patients, impact different factors on immune response. From September 2021 April 2022, outpatients CLD who completed primary vaccination course dose against SARS-CoV-2 were enrolled. Blood samples collected after second third for detecting anti-spike protein IgG. enrolled 340 patients; among them, 91 subjects cirrhotic. After course, 60 (17.6%) did not develop positive antibody titer, without significant differences between (p = 0.076); most them (88.3%) developed it dose. At multivariable analysis, associated higher only porto-sinusoidal vascular disorder 0.007) as an etiology use mRNA-1273 vaccine 0.001). In conclusion, CLD, induces excellent leads adequate Cirrhosis worse response, compared CLD.

Language: Английский

Citations

6
COVID-19 vaccination and liver disease DOI Creative Commons
Sotaro Ozaka, Takashi Kobayashi, Kazuhiro Mizukami

et al.

World Journal of Gastroenterology, Journal Year: 2022, Volume and Issue: 28(48), P. 6791 - 6810

Published: Dec. 26, 2022

Various vaccines against severe acute respiratory syndrome coronavirus 2 have been developed in response to the disease 2019 (COVID-19) global pandemic, several of which are highly effective preventing COVID-19 general population. Patients with chronic liver diseases (CLDs), particularly those cirrhosis, considered be at a high risk for and death. Given increased rates severity mortality patients disease, there is an urgent need understand efficacy vaccination this However, data regarding safety CLDs limited. Indeed, organ-specific or systemic immune-mediated side effects following vaccination, including injury similar autoimmune hepatitis, recently reported. Although number cases vaccine-related increasing, its frequency, clinical course, mechanism remain unclear. Here, we review current findings on focusing on: (1) The impact CLD; (2) efficacy, safety, risk-benefit profiles (3) Liver vaccination.

Language: Английский

Citations

9
Efficacy, Safety and Immunogenicity of Anti-SARS-CoV-2 Vaccines in Patients with Cirrhosis: A Narrative Review DOI Creative Commons

Konstantina Toutoudaki,

Melitini Dimakakou,

Θεόδωρος Ανδρουτσάκος

et al.

Vaccines, Journal Year: 2023, Volume and Issue: 11(2), P. 452 - 452

Published: Feb. 16, 2023

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing disease 2019 (COVID-19), has led to a pandemic with more than 6.5 million deaths worldwide. Patients liver cirrhosis (PWLC) are regarded as prone severe COVID-19. Vaccination against SARS-CoV-2 been proven be the most effective measure COVID-19 and variety of different vaccines have approved for use; namely mRNA vector-based, inactivated, whole virion, protein subunit vaccines. Unfortunately, only small number PWLC were included in phase I–III vaccine trials, raising concerns regarding their efficacy safety this population. The authors, review, present available data anti-SARS-CoV-2 vaccination discuss post-vaccination antibody responses. Overall, all seem extremely safe, few insignificant adverse events, efficient, leading lower rates hospitalization COVID-19-related mortality. T- B-cell responses, on other hand, remain an enigma, especially patients decompensated disease, since these show titers antibodies some studies, rapid waning. However, finding is not consistent, its clinical impact still undetermined.

Language: Английский

Citations

5
SARS-CoV-2 and chronic hepatitis B: Focusing on the possible consequences of co-infection DOI Creative Commons
Shahrzad Shoraka, Seyed Reza Mohebbi, Seyed Masoud Hosseini

et al.

Journal of Clinical Virology Plus, Journal Year: 2023, Volume and Issue: 3(4), P. 100167 - 100167

Published: Oct. 14, 2023

The pandemic of 2019 coronavirus disease (COVID-19) has become a world public health challenge. A new member Coronaviridae family, named severe acute respiratory syndrome 2 (SARS-CoV-2), been identified as the causative COVID-19. Although SARS-CoV-2 infection direct impact on function, extra-respiratory complications such liver damage have reported in some cases. However, exact mechanisms injury remain largely unexplored. It also suggested that patients with pre-existing are significantly influenced by Considering double burden chronic diseases and systems, investigating interrelationship between COVID-19 underlying providing clear recommendations treatment very much needed. Viral hepatitis is recognized one substantial risk factors for diseases. Hepatitis B virus (HBV) main cause failure, cirrhosis hepatocellular carcinoma (HCC). Since both HBV affect physiology, possible interactions effects SARS-CoV-2/HBV co-infection increasingly important. This review highlighted molecular clinical consequences co-infection.

Language: Английский

Citations

5
Inactivated vaccines reduce the risk of liver function abnormality in NAFLD patients with COVID-19: a multi-center retrospective study DOI Creative Commons
Zhixue Chen, Wenqing Tang, Nana Feng

et al.

EBioMedicine, Journal Year: 2023, Volume and Issue: 99, P. 104912 - 104912

Published: Dec. 13, 2023

Abnormal liver function was frequently observed in nonalcoholic fatty disease (NAFLD) patients infected with SARS-CoV-2. Our aim to explore the effect of SARS-CoV-2 inactivated vaccines on abnormality among NAFLD COVID-19.

Language: Английский

Citations

4